KineMed Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:KineMed Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013233
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:32
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
KineMed Inc (KineMed) is a biotechnology company that develops and commercializes proprietary biomarker platform technology. The company applies its proprietary biomarker platform technology to drug development, prescription, and non-prescription medical diagnostics and the pairing of drugs with diagnostic biomarker tests. It utilizes isotope labeling, mass spectrometry, and other techniques to observe the activity of biochemical pathways, measure molecular fluxes within the pathways, and to monitor the appearance and disappearance of individual proteins and biological biomarkers. Kinmed develops drugs in the therapeutic areas of muscle metabolism, fibrosis, immunity, neurobiology, diabetes, cancer, and others. The company also conducts pharmaceutical research on molecular targets and deconstructed systems. KineMed is headquartered in Emeryville, California, the US.

KineMed Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
KineMed Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
KineMed Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
KineMed Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
KineMed Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
KineMed Inc, Medical Devices Deals, 2011 to YTD 2017 9
KineMed Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
KineMed Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
KineMed Raises Additional USD0.45 Million in Venture Financing 11
KineMed Raises USD1.69 Million in Venture Financing 12
KineMed Raises US$2 Million In Venture Financing 13
KineMed Raises US$1 Million In Venture Financing 14
Kinemed Secures Additional US$1.9 Million In Series F Financing 15
Partnerships 16
Neurotez Partners with KineMed 16
KineMed Enters into R&D Agreement with Pronutria Biosciences 17
KineMed Extends Research Agreement with Pfizer for Metabolic Disease Therapies 18
KineMed Enters Into Agreement With EMD Serono To Identify Protein And Lipid Biomarkers 19
KineMed Extends Research Agreement With Pfizer 20
KineMed Enters Into Co-Development Agreement With Pfizer 21
PsychoGenics Enters Into Joint Venture Agreement With KineMed 22
Licensing Agreements 23
Oxeia Biopharma Enters into Licensing Agreement with Kinemed 23
Pfizer Enters into Licensing Agreement with KineMed 24
KineMed Enters into Licensing Agreement with BioPharma Forest 25
KineMed Extends Licensing Agreement With Bristol-Myers Squibb 26
Equity Offering 27
KineMed Withdraws IPO 27
KineMed Inc – Key Competitors 29
KineMed Inc – Key Employees 30
KineMed Inc – Locations And Subsidiaries 31
Head Office 31
Appendix 32
Methodology 32
About GlobalData 32
Contact Us 32
Disclaimer 32

List of Tables
KineMed Inc, Pharmaceuticals & Healthcare, Key Facts 2
KineMed Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
KineMed Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
KineMed Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
KineMed Inc, Deals By Therapy Area, 2011 to YTD 2017 8
KineMed Inc, Medical Devices Deals, 2011 to YTD 2017 9
KineMed Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
KineMed Raises Additional USD0.45 Million in Venture Financing 11
KineMed Raises USD1.69 Million in Venture Financing 12
KineMed Raises US$2 Million In Venture Financing 13
KineMed Raises US$1 Million In Venture Financing 14
Kinemed Secures Additional US$1.9 Million In Series F Financing 15
Neurotez Partners with KineMed 16
KineMed Enters into R&D Agreement with Pronutria Biosciences 17
KineMed Extends Research Agreement with Pfizer for Metabolic Disease Therapies 18
KineMed Enters Into Agreement With EMD Serono To Identify Protein And Lipid Biomarkers 19
KineMed Extends Research Agreement With Pfizer 20
KineMed Enters Into Co-Development Agreement With Pfizer 21
PsychoGenics Enters Into Joint Venture Agreement With KineMed 22
Oxeia Biopharma Enters into Licensing Agreement with Kinemed 23
Pfizer Enters into Licensing Agreement with KineMed 24
KineMed Enters into Licensing Agreement with BioPharma Forest 25
KineMed Extends Licensing Agreement With Bristol-Myers Squibb 26
KineMed Withdraws IPO 27
KineMed Inc, Key Competitors 29
KineMed Inc, Key Employees 30

★海外企業調査レポート[KineMed Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Grupo Aeroportuario del Centro Norte SAB de CV:企業の戦略・SWOT・財務情報
    Grupo Aeroportuario del Centro Norte SAB de CV - Strategy, SWOT and Corporate Finance Report Summary Grupo Aeroportuario del Centro Norte SAB de CV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, ope …
  • Solvay S.A:企業の戦略・SWOT・財務分析
    Solvay S.A - Strategy, SWOT and Corporate Finance Report Summary Solvay S.A - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Takeda Pharmaceutical Co Ltd (4502):製薬・医療:M&Aディール及び事業提携情報
    Summary Takeda Pharmaceutical Company Ltd (Takeda) is a research-based global pharmaceutical company which focuses on the research and development, manufacture, marketing, commercialization and import and export of pharmaceutical drugs and consumer health care products. The company manufactures and …
  • Titanium Metals Corp:企業の戦略・SWOT・財務分析
    Titanium Metals Corp - Strategy, SWOT and Corporate Finance Report Summary Titanium Metals Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Banque de France:企業の戦略的SWOT分析
    Banque de France - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Sirona Biochem Corp (SBM):企業の財務・戦略的SWOT分析
    Summary Sirona Biochem Corp (Sirona Biochem) is a biotechnology company that discovers and develops therapeutics, cosmeceuticals and biological ingredients. The company develops drugs for diabetes and cancer. It offers cosmeceutical programs such as development of anti-aging and depigmenting agents, …
  • ABPA Holdings Limited:企業の戦略的SWOT分析
    ABPA Holdings Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Quantum Utility Generation LLC:電力:M&Aディール及び事業提携情報
    Summary Quantum Utility Generation LLC (QUG) is an electric utility that acquires, develops, operates and optimizes power generation assets in the Americas. The utility generates electricity from various sources such as wind, coal and natural gas-based power generation plants. It also produces elect …
  • LinkedIn Corp:企業の戦略的SWOT分析
    LinkedIn Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • UltraTech Cement Ltd:戦略・SWOT・企業財務分析
    UltraTech Cement Ltd - Strategy, SWOT and Corporate Finance Report Summary UltraTech Cement Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Stanwell Corporation Ltd:企業の戦略的SWOT分析
    Stanwell Corporation Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Hersha Hospitality Trust:企業のM&A・事業提携・投資動向
    Hersha Hospitality Trust - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Hersha Hospitality Trust Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • Regulus Therapeutics Inc (RGLS):医療機器:M&Aディール及び事業提携情報
    Summary Regulus Therapeutics Inc (Regulus Therapeutics) is a biopharmaceutical company that discovers and develops microRNA based therapeutics. The company provides single stranded oligonucleotides, which are chemically synthesized chains of nucleotides that are mirror images of specific target micr …
  • TOR Minerals International Inc (TORM):企業の財務・戦略的SWOT分析
    Summary TOR Minerals International Inc (TOR) is a chemical company that manufactures and distributes mineral and pigment products. The company provides products such as optiload, aluprem, haltex, and others. It also offers alumina trihydrate and boehmite halogen-free flame retardant and smoke suppre …
  • Advaxis Inc (ADXS):企業の財務・戦略的SWOT分析
    Advaxis Inc (ADXS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Jersey Oil and Gas Plc (JOG):企業の財務・戦略的SWOT分析
    Summary Jersey Oil and Gas Plc (Jersey Oil), formerly Trap Oil Group Plc is an upstream oil and gas exploration and production company. The company acquires, explores, develops and produces natural gas properties in the UK continental shelf. Its oil and gas properties include Homer Block, Cortina Bl …
  • Hisamitsu Pharmaceutical Co Inc (4530):製薬・医療:M&Aディール及び事業提携情報
    Summary Hisamitsu Pharmaceutical Co Inc (Hisamitsu Pharmaceutical) is a pharmaceutical company that provides pain management products. The company manufactures and sells pain relieving products, dermatological products, and quasi drugs, among others. Hisamitsu Pharmaceutical provides its products in …
  • Sumitomo Corp (8053):企業の財務・戦略的SWOT分析
    Sumitomo Corp (8053) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Xcel Energy Inc:企業の発電所・SWOT分析2018
    Xcel Energy Inc - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (ex …
  • Erin Energy Corp (ERINQ):石油・ガス:M&Aディール及び事業提携情報
    Summary Erin Energy Corp (Erin Energy), formerly CAMAC Energy Inc, a subsidiary of CAMAC Energy Holdings Ltd, is an oil and gas company that develops and produces oil and gas assets. The company's portfolio includes seven licenses in four countries and covers an area of approximately 19,000 sq km of …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆